EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Christopher N Schmickl iD, Jeremy E Orr, Raichel M Alex, Eli Gruenberg, Gabriela Parra, Stephanie White, Alex Spenceley, Tia DeSarkar, Mitchell Kong, Pamela N DeYoung, Scott A Sands iD, Robert L Owens und 1 weitere

Annals of the American Thoracic Society · 2025

DOI: 10.1513/annalsats.202407-736oc ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the American Thoracic Society, 2025. Verfasst von Christopher N Schmickl und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology and. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Venlafaxine Hydrochloride, Acetazolamide, Eszopiclone. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, American Heart Association-American Stroke Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Acetazolamide, eszopiclone, and venlafaxine may target different underlying mechanisms of obstructive sleep apnea (OSA) and individually may partially reduce OSA severity in select patients. We tested whether acetazolamide plus eszopiclone (DualRx) reduces OSA severity. We further explored whether the addition of venlafaxine (TripleRx) alleviates OSA in patients who do not fully respond to DualRx.

Methods

In this double-blind crossover trial, 20 patients with OSA underwent baseline polysomnography followed by DualRx/placebo phases in random order. Subsequently, 18 patients underwent an open-label TripleRx phase. Each phase lasted 3 days and concluded with polysomnography. The primary outcome was the placebo-adjusted change in apnea–hypopnea index during supine, non–rapid eye movement sleep (AHINREM,supine) from baseline to DualRx. Secondary outcomes included other OSA metrics, sleep parameters, and select clinical outcomes (blood pressure, symptoms, and vigilance).

Results

Participants were on average middle aged, overweight, and relatively diverse (20% women, 60% non-White), with severe OSA (median [interquartile range] AHINREM,supine, 32.8 [20 to 48.8] events/h). Compared with placebo, DualRx was well tolerated and improved AHINREM,supine (−13.8 [−24.1 to −5.2] events/h or −45% [−77% to −14%]; P Wilcoxon = 0.003), overall AHI, hypoxic burden, and sleep architecture (P < 0.05) but not the selected clinical outcomes. TripleRx did not provide a clear benefit relative to DualRx, although some measures of OSA-related hypoxemia improved more substantially. There were no serious side effects.

Conclusions

Short-term use of dual-drug therapy with DualRx substantially reduced OSA severity. Adding venlafaxine did not generally reduce OSA severity but may be beneficial for some patients. Longer term studies are needed to assess effects on clinically important outcomes. Clinical trial registered with www.clinicaltrials.gov (NCT04639193).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, ObstructiveVenlafaxine HydrochlorideAcetazolamideEszopicloneHumansFemaleDouble-Blind MethodMaleMiddle AgedPolysomnographyCross-Over StudiesDrug Therapy, CombinationTreatment OutcomeAdultHypnotics and SedativesSeverity of Illness IndexAged

Stichwörter der Autor:innen

acetazolamideeszopicloneobstructive sleep apneavenlafaxine

Substanzen

Venlafaxine HydrochlorideAcetazolamideEszopicloneHypnotics and Sedatives

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology and.
  • Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Department of Bioengineering, University of California, San Diego, San Diego, California; and.

ORCID-Profile: Christopher N Schmickl, Scott A Sands

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • American Heart Association-American Stroke Association
  • NIA NIH HHS
  • American Heart Association
  • American Thoracic Society
  • AASMF
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Schmickl, C. N., Orr, J. E., Alex, R. M., Gruenberg, E., Parra, G., White, S., Spenceley, A., DeSarkar, T., Kong, M., DeYoung, P. N., Sands, S. A., Owens, R. L., & Malhotra, A. (2025). Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.202407-736oc

Vancouver

Schmickl CN, Orr JE, Alex RM, Gruenberg E, Parra G, White S, et al. Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Annals of the American Thoracic Society. 2025. doi:10.1513/annalsats.202407-736oc

BibTeX
@article{Schmickl2025,
  author = {Schmickl, Christopher N and Orr, Jeremy E and Alex, Raichel M and Gruenberg, Eli and Parra, Gabriela and White, Stephanie and Spenceley, Alex and DeSarkar, Tia and Kong, Mitchell and DeYoung, Pamela N and Sands, Scott A and Owens, Robert L and Malhotra, Atul},
  title = {Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial},
  journal = {Annals of the American Thoracic Society},
  year = {2025},
  doi = {10.1513/annalsats.202407-736oc}
}
Kostenlos starten →